(Bega et al. 2021) In addition to its supportive role in the differential diagnosis of non-dopamine deficiency aetiologies of movement disorders, DaTscanTM may potentially serve as a clinical biomarker for outcome prediction, since striatal DAT availability correlates with the burden of parkinsonian motor symptoms and striatal DAT binding decreases progressively with increasing disease severity. This evidence concerns the gene SLC6A3 and movement disorder.